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Mitochondrial diseases are clinically and genetically heterogeneous disorders,
caused by pathogenic variants in either the nuclear or mitochondrial genome.
This heterogeneity is particularly striking for disease caused by variants in
mitochondrial DNA-encoded tRNA (mt-tRNA) genes, posing challenges for
both the treatment of patients and understanding the molecular pathology. In
this review, we consider disease caused by the two most common pathogenic
mt-tRNA variants: m.3243A>G (within MT-TL1, encoding mt-tRNALeu(UUR))
and m.8344A>G (within MT-TK, encoding mt-tRNALys), which together
account for the vast majority of all mt-tRNA-related disease. We compare and
contrast the clinical disease they are associated with, as well as their molecular
pathologies, and consider what is known about the likely molecular mecha-
nisms of disease. Finally, we discuss the role of mitochondrial–nuclear cross-
talk in the manifestation of mt-tRNA-associated disease and how research in
this area not only has the potential to uncover molecular mechanisms responsi-
ble for the vast clinical heterogeneity associated with these variants but also
pave the way to develop treatment options for these devastating diseases.
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Mitochondria are the principal generators of adenosine
triphosphate (ATP) within eukaryotic cells via a pro-
cess referred to as oxidative phosphorylation
(OXPHOS). Mitochondria are double membrane-
bound organelles that are uniquely controlled by their
own multicopy genome and that of the nucleus. The
human mitochondrial DNA (mtDNA) is a maternally
inherited double-stranded circular genome of
16 569 bp. The overwhelming majority of mitochon-
drial proteins are encoded by the nuclear genome [1],
but the mtDNA encodes 13 polypeptides, each of which
forms a core subunit in one of the OXPHOS
complexes, with the exception of complex II, which is
entirely nuclear-encoded (Fig. 1A) [2,3]. To translate
these 13 mtDNA-encoded proteins, mitochondria con-
tain their own set of ribosomes; the proteins for the
mitochondrial translation machinery are nuclear-en-
coded, translated in the cytoplasm and transported into
the mitochondrial matrix, but all of the essential RNA
species (16S and 12S ribosomal RNAs and 22 mt-
tRNAs) are mtDNA-encoded [4]. The dual genetic ori-
gin of mitochondrial ribosomes and the respiratory
chain imposes a unique challenge for human cells, the
need to tightly coordinate the expression of the
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mitochondrial genome with the nucleo-cytoplasmic
gene expression machinery. Failure to coordinate these
processes results in stress and dysfunction, triggering
surveillance mechanisms to protect the cell from disrup-
tions in mitochondria. However, chronic perturbations
of the system will ultimately lead to human disease [5].
Pathogenic variants in mitochondrial tRNAs cause a
wide range of disease phenotypes, but high-energy-con-
suming tissues such as those forming the neuromuscu-
lar and nervous systems are particularly vulnerable. As
outlined above, mt-tRNAs are required for mitochon-
drial protein biosynthesis. Establishing a fully func-
tional tRNA molecule (cytoplasmic or mitochondrial)
requires a multitude of post- and cotranslational modi-
fication steps, including 50 and 30 processing, CAA
addition and aminoacylation, as well as a myriad of
chemical RNA base modifications. tRNA-modifying
enzymes (writer enzymes) have been reported to
account for more than a hundred distinct post-tran-
scriptional modifications on both the ribonucleotide
purine/pyrimidine bases and the sugar backbone. The
mt-tRNA-modifying enzymes and the consequential
mt-tRNA modifications (Fig. 1B) constitute another
level of structural information ancillary to the primary
structure for folding and recognition, and have both
been associated with human pathologies [].
Throughout evolution, mammalian mt-tRNA genes
have also accumulated mutations at significantly
higher rate compared with their cytoplasmic counter-
parts, and as a result, human mt-tRNAs are struc-
turally condensed and fragile. It has been suggested
that this reduced structural complexity in mammalian
mt-tRNAs is compensated by primary sequence-inde-
pendent induced-fit adaptation of and to the cognate
mitochondrial aminoacyl-tRNA synthetases (mt-
aaRSs) [7]. This interaction has potentially important
implications for our understanding of mt-tRNA muta-
tion disease and pathology. In line with this
evolutionary trend, the majority of disease-causing
mtDNA mutations in humans are mapped to mt-
tRNA genes. However, the highly polymorphic nature
of mt-tRNA genes hampers the characterisation of
novel substitutions found in patients as pathogenic.
Also, genetic heterogeneity between cells and tissues
seems to be highly relevant for diseases caused by mt-
tRNA mutations and a better understanding of the
very complex genotype–phenotype relationship in this
group of disorders is of the greatest importance [8,9].
As exemplars of mitochondrial disease caused by
defects in mt-tRNA molecules, we consider the two
most common pathogenic mt-tRNA variants, namely
m.3243A>G (within MT-TL1, encoding mt-tRNALeu
(UUR)) and m.8344A>G (within MT-TK, encoding mt-
tRNALys), which together account for ~ 85% of all
mt-tRNA-related mitochondrial disease [10]. They
both pose significant challenges for clinical manage-
ment and genetic counselling as their phenotypic spec-
tra are highly heterogeneous, disease burden varies
widely between patients, and treatment options are
limited. This complexity is linked with the multicopy
nature of mtDNA, which permits the existence of
more than one species of mtDNA molecule within a
cell, a status known as heteroplasmy (Box 1). Both
m.3243A>G and m.8344A>G are heteroplasmic, and
the proportion of the disease-associated allele can vary
from 0% to near 100%. Maternal transmission of
these heteroplasmic variants through the mitochondrial
bottleneck in oogenesis results in variable levels of the
pathogenic allele in the offspring of female carriers,
contributing to this heterogeneity and highlighting the
importance of providing reproductive options for
female carriers (reviewed in Ref. [11]). Understanding
the molecular pathogenesis of these variants and how
they cause such varied disease is critically important
for the clinical management of patients, but there is
much we currently do not know.
Fig. 1. Mitochondrial tRNAs are encoded by the human mitochondrial genome. (A) Schematic representation of the double-stranded circular
human mitochondrial DNA (16.6 kb). The outer circle represents the guanine-rich heavy strand, which is transcribed from heavy strand
promoters 1 and 2 (HSPs), and the inner circle represents the cytosine-rich light strand, transcribed from the light-strand promoter (LSP).
Thirteen protein-coding genes encode essential components of the respiratory chain: seven complex I (green; MT-ND1 to MT-ND6 and MT-
ND4L); one complex III (purple; MT-CYB); three complex IV (yellow; MT-CO1 to MT-CO3); and two mitochondrial ATP synthase (blue; MT-
ATP6 and MT-ATP8) subunits. The mitochondrial genome also encodes all of the RNA species required for translation of these polypeptides:
MT-RNR1 and MT-RNR2 encode mitochondrial 12S and 16S rRNAs (red), and 22 genes encoding mt-tRNA molecules are distributed
throughout the genome (grey bars; mt-tRNA molecules illustrated as clover-leaf structures with three letter amino acid codes). The two
pathogenic variants discussed in this review, m.3243A>G and m.8344A>G, are found within the genes for mt-tRNALeu(UUR) (Leu-1) and mt-
tRNALys (Lys), which are highlighted in red. (B) Schematic depicting the secondary structure of mitochondrial mt-tRNALeu(UUR) and mt-
tRNALys highlighting the position of m.3243A>G and m.8344A>G (red). Specific RNA modifications and their responsible ‘writer’ enzymes
are colour-coded. Abbreviations for modified nucleosides are as follows: m1A (1-methyladenosine), m1G (1-methylguanosine), m2G
(N2-methylguanosine), m5C (5-methylcytidine), sm5U (5-taurinomethyluridine), sm5s2U (5-taurinomethyl-2-thiouridine), t6A
(N6-threonylcarbamoyladenosine), Ψ (pseudouridine).
1005FEBS Letters 595 (2021) 1003–1024 ª 2021 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
U. Richter et al. Pathogenic mitochondrial tRNA variants
Box 1. Heteroplasmy
A: Intracellular variability. The multicopy nature of the mitochondrial genome gives rise to heteroplasmy; the coexis-
tence of more than one species of mtDNA molecule within the same cell. Consequently, the proportion of variant
alleles within cells can vary from 0% to 100%. Cells at the extremes, containing only one mtDNA species, are termed
homoplasmic. Cells that contain a mixture of mtDNA species are termed heteroplasmic. Both m.3243A>G and
m.8344A>G are heteroplasmic mtDNA variants, as depicted by the presence of both wild-type (blue) and variant
(red) alleles within the same cell.
B: Schematic representation of skeletal muscle tissue showing variability in heteroplasmy between fibres. Cells within tis-
sues show mosaicism; the majority of cells will be heteroplasmic but it is possible for some cells to become homoplas-
mic, or near homoplasmic, for either wild-type or variant alleles. Both random segregation of mitochondria into
daughter cells during cell division and clonal expansion (due to either random or selective mtDNA replication) con-
tribute to this heterogeneity. The underlying distribution of heteroplasmy within the tissue can be assessed using
quantitative, single-cell assessments.
C: Levels of m.3243A>G vary between tissues within an individual. Blood, urine and skeletal muscle samples are fre-
quently taken to assess carrier status and heteroplasmy for pathogenic mtDNA variants as they are relatively easily
accessible. These measurements represent homogenate tissue levels, and they can vary from tissue to tissue. For
m.3243A>G, mitotic tissues, such as blood, show an age-related decline in levels of the pathogenic allele and levels in
urine are highly variable, whereas levels are more stable in muscle. In patients with the m.8344A>G variant, levels of
the pathogenic allele are uniformly distributed across all tissues.
In this review, we outline the phenotypic spectra
associated with both m.3243A>G and m.8344A>G
and the complexities involved in assessing the effect
of variant allele heteroplasmy level on disease burden.
Although both variants affect the translation of
mtDNA-encoded proteins and consequently impact
OXPHOS function, their molecular pathology and
the role of the nucleus in the cellular response to
their presence, such as the mitochondrial integrated
stress response (ISRmt), are not fully understood. We
also discuss the advantages of using patient-derived
tissue to study the underlying pathogenic molec-
ular mechanisms and cellular responses and con-
sider how hypothesis-driven and knowledge-discovery
approaches can be combined to identify factors
involved in the vast phenotypic heterogeneity of mt-
tRNA-related disease, with the ultimate aim of
improving patient care.
1006 FEBS Letters 595 (2021) 1003–1024 ª 2021 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
Pathogenic mitochondrial tRNA variants U. Richter et al.
Variability in disease burden and
progression
Clinical phenotypes of m.3243A>G
The heteroplasmic m.3243A>G variant was first identi-
fied as pathogenic 30 years ago, within a cohort of
patients suffering from a maternally inherited syn-
drome characterised by mitochondrial myopathy,
encephalopathy and stroke-like episodes (MELAS)
[12–14]. Aetiologically distinct from vascular strokes,
the stroke-like episodes associated with MELAS are
acute or subacute metabolic crises resulting in brain
lesions that often cross anatomical, vascular bound-
aries and frequently occur before the age of 40 years
[15]. Although it has been estimated that 80% of
MELAS cases are caused by m.3243A>G [16–18], rarer
mtDNA variants have also been associated with this
neurometabolic syndrome, including the m.3271T>C
and m.3291T>C MT-TL1 variants [16,19]. Pathogenic
variants within 10 other mt-tRNA genes [20–32] and
variants in genes encoding mtDNA-encoded structural
subunits of complex I, complex III and complex IV
also cause MELAS [33–41]. A MELAS-like phenotype
associated with mutations in the nuclear gene encoding
the catalytic subunit of the mitochondrial DNA poly-
merase gamma (POLG) has also been reported [42].
Despite its initial identification in patients with
MELAS, only 15–40% of patients clinically diagnosed
as carriers of m.3243A>G have a MELAS diagnosis
[43,44]. The most common syndrome associated with
m.3243A>G is MIDD (maternally inherited diabetes
and deafness) [45], but PEO (progressive external oph-
thalmoplegia) [46] and, more rarely, MERRF [47] and
Leigh syndrome (a progressive subacute-necrotising
encephalomyelopathy, often presenting within the first
months or years of life) [48] are also associated. How-
ever, classifying patients by these classic syndromes
does not fully describe the wide phenotypic spectrum;
many patients exhibit overlap syndromes, some display
phenotypes that do not fit a syndromic diagnosis, and
others are asymptomatic [43].
Cohort studies can give us insight into the relative
incidence of the large number of clinical phenotypes
associated with m.3243A>G and are less susceptible to
publication bias than case studies, although differences
in ascertainment and diagnostic criteria can make
comparisons between studies challenging [43,44,49–52].
Nevertheless, it is clear that hearing loss, gastrointesti-
nal disturbances, diabetes/glucose intolerance, cerebel-
lar ataxia, myopathy/exercise intolerance, cardiac
involvement, ptosis and psychiatric involvement are
among the most common m.34243A>G-related
phenotypic features (Fig. 2). The reported incidence of
stroke-like episodes in m.3243A>G carriers varies con-
siderably, probably reflecting differing ascertainment
and follow-up strategies; the frequency is 17% in the
UK Mitochondrial Disease Patient Cohort and 5% in
a Dutch cohort of 34 pedigrees, both of which have
actively recruited matrilineal relatives of probands,
whereas the Nationwide Italian Collaborative Network
of Mitochondrial Diseases cohort reports 40%
[44,50,52].
Other reported clinical features include cognitive
impairment/developmental delay [49], neuropathy [53],
PEO [46], retinopathy [54], optic neuropathy [47], dys-
phonia/dysarthria [52,55], migraine [56], growth fail-
ure/short stature [57] and sudden adult death [58].
Less frequently, m.3243A>G has also been associated
with a wide range of additional features, including
renal failure [59], neuroendocrine dysfunction [60] and
vasculitis [61], further widening the phenotypic spec-
trum associated with this variant.
Disease related to m.3243A>G is progressive and
results in a phenotypic profile that changes over time.
This is exemplified in an Italian cohort study (n = 126;
6.3% asymptomatic), which reported hearing loss
(31%), generalised seizures (18%) and diabetes (18%)
as the most common phenotypes at disease onset (mean
age of onset in symptomatic patients was 23.4
 15.6 years). At last evaluation (36.0  20.7 years),
these had all increased in frequency (58%, 37% and
41%, respectively) and ptosis/ophthalmoparesis,
migraine, muscle weakness, exercise intolerance and
heart disease were also present at a frequency > 30%
[44]. Progressive disease in patients with MELAS and
their carrier relatives has also been reported in a
prospective cohort study of American patients [49]. Sig-
nificant associations between some traits hint towards a
similar underlying aetiology or a contemporaneous
trigger in already vulnerable tissues, for example sei-
zures, encephalopathy and stroke-like episodes; dia-
betes and deafness; cognitive impairment with a
number of CNS traits (e.g. stroke-like episodes,
encephalopathy, cerebellar ataxia and dysphonia/dysar-
thria); and cerebellar ataxia with a number of traits
(e.g. myopathy, hearing impairment and dysphonia/
dysarthria) [52].
These headline figures give us an indication of the
broad range of phenotypic features associated with
m.3243A>G, but many show a wide range of severities
and are often progressive; for example, ‘gastrointesti-
nal disturbances’ could be characterised by episodes of
irritable bowel and/or constipation but can also indi-
cate that a patient has experienced severe gastrointesti-
nal pseudo-obstruction (paralytic ileus; ~ 10%
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patients), which can be fatal in the situation of con-
comitant stroke-like episodes [62]. Similarly, psychi-
atric involvement is observed in ~ 70% and can often
be mild and transient (e.g. a short period of depres-
sion), but in ~ 20–40%, it can be more severe, war-
ranting specialist treatment (e.g. bipolar disorder,
psychosis, self-harm or suicide attempts), and may be
linked to cerebellar atrophy [52,63–65]. Clinically vali-
dated scores such as the Newcastle Mitochondrial Dis-
ease Adult Scale (NMDAS) and the Newcastle
Paediatric Mitochondrial Disease Scale (NPMDS) can
be used to record both the presence and severity of
phenotypes, aiding more direct comparisons between
cohorts [66,67].
Clinical phenotypes of m.8344A>G
The involvement of mitochondrial dysfunction in a
syndrome characterised by myoclonus (quick, involun-
tary skeletal muscle jerks), and epilepsy was reported
in two unrelated patients by Fukuhara et al. [68] in
1980, and termed MERRF (myoclonic epilepsy associ-
ated with ragged-red fibres). Ragged-red fibres
(RRFs), so named due to their excessively red appear-
ance when stained with Gomori’s trichrome and the
ragged outer edge of the fibre caused by the accumula-
tion of abnormal subsarcolemmal mitochondria, are
histopathological hallmarks of mitochondrial disease
observed in patient muscle biopsies [68,69]. A decade
later, after Wallace et al. [70] had demonstrated the
presence of a maternally inherited mtDNA variant, a
heteroplasmic A-to-G transition at position 8344 in
the mitochondrial genome within MT-TK was identi-
fied as the cause of MERRF syndrome [71], a finding
that was corroborated later that year [72]; further evi-
dence suggested that it was pathogenic, causing abnor-
mal mitochondrial translation, and was shown to have
arisen independently in three different individuals with
MERRF [73]. Other variants within MT-TK have also
been associated with the MERRF phenotype, for
example m.8356T>C and m.8363G>A [74,75], as well
as variants in five other mt-tRNA genes
Fig. 2. Comparison of the phenotypic features of m.3243A>G and m.8344A>G-related disease. For m.8344A>G, phenotypic frequencies (at
last evaluation) were obtained from Refs [95,97]. For m.3243A>G, frequencies were obtained from Refs [44,50–52,65]. Phenotypes are
grouped into neurological (purple), muscle-related (red) and others (light blue) and ordered by frequency in m.3243A>G patients. Stroke-like
episodes, cognitive impairment, diabetes and gut dysmotility are notably higher in frequency in m.3243A>G patients, whereas ataxia,
psychiatric features, myoclonus and myopathy/exercise intolerance are higher in m.8344A>G patients. Lipomas are a noticeable feature of
m.8344A>G but not m.3243A>G-related disease. For phenotypes where more than one estimate of frequency is reported in the literature,
the highest estimate is shown in a lighter shade, with the lowest estimate in a darker shade, thus depicting an estimated range.
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[21,27,47,76,77] and MT-ND5 [78], but m.8344A>G
remains the most common pathogenic variant associ-
ated with the MERRF phenotype [10].
In the 30 years since the identification of
m.8344A>G, over 350 additional mutation carriers
have been reported in the literature and the phenotypic
spectrum associated with this pathogenic variant has
expanded from the canonical phenotypes of myoclo-
nus, seizures, cerebellar ataxia and mitochondrial
myopathy to include many others such as hearing
impairment [71], lipomas [79], ptosis and ophthalmo-
paresis [80], cardiac abnormalities [81,82], respiratory
impairment with sleep disorders [83] and diabetes [84]
(Fig. 2).
Less commonly, m.8344A>G has been reported to
cause a severe childhood presentation of Leigh syn-
drome, global developmental delay, hypotonia, ataxia,
dystonia and ophthalmologic abnormalities [46,85–89].
m.8344A>G is also the cause of the independently
described Ekbom’s syndrome (photomyoclonus, cere-
bellar ataxia and cervical lipoma) [90]. Stroke-like epi-
sodes and gastrointestinal dysfunction (paralytic ileus),
both more commonly associated with the m.3243A>G
variant, have also been linked to m.8344A>G [91].
Distal weakness with respiratory insufficiency was
reported in one patient [92] and Parkinsonism in
another [93], although m.8344A>G is not a common
cause of Parkinsonism [94]. Although many of these
studies have not investigated the possibility of the
presence of mtDNA cis-modifiers, some report familial
studies in which other maternal relatives do not exhibit
such severe clinical manifestations, suggesting that
something else may be modulating the phenotype in
these individuals [85,88]. However, maternal inheri-
tance of more severe phenotypes has been observed in
some pedigrees, which might indicate the presence of
cis-modifiers [86,87].
As m.8344A>G is less frequent than m.3243A>G,
fewer and smaller cohort studies have been performed,
but they still provide insight into the full phenotypic
spectrum. Mancuso et al. [95] reported phenotype data
from 42 individuals carrying m.8344A>G, representing
12.4% of all patients with pathogenic mtDNA variants
in the Italian Collaborative Network of Mitochondrial
Diseases. The mean age of onset was 30.1  18.4 years
(range 0–66), although they observed childhood onset
(< 16 years) in 35.7% and about 10% were asymp-
tomatic. Signs of neuromuscular dysfunction were pre-
sent in 76.5% of symptomatic adult patients,
consistent with a previous study [96]; muscle weakness
(58.8%), exercise intolerance (44.1%), generalised sei-
zures (35.3%), hearing loss (35.3%) and multiple lipo-
mas (32.4%) were also common phenotypes (> 30%).
By combining clinical data from their 42 individuals
with that of 282 cases available in the literature, Man-
cuso et al. estimated that the most common pheno-
types across all reported carriers were myoclonus,
muscle weakness and ataxia (35–45%), followed by
generalised seizures and hearing loss (25–34.9%), then
cognitive impairment, multiple lipomas, neuropathy
and exercise intolerance (15–24.9%). The least com-
mon were ptosis/ophthalmoparesis, optic atrophy, car-
diomyopathy, muscle wasting, respiratory impairment,
diabetes, muscle pain, tremor and migraine (5–14.9%)
[95].
A more recent cohort study from the German net-
work for mitochondrial disorders (mitoNET) reported
a slightly lower age of onset (24.5  10.9 years; range
6–48) but with a similar rate of childhood onset (25%)
[97]. These authors reported that a larger proportion of
patients had myoclonus, muscle weakness, ataxia, sei-
zures and hearing loss (58–72%), respiratory impair-
ment, increased CK, migraine and psychiatric
involvement (45–54%) and gastrointestinal dysmotility
and swallowing impairment (35–38%). However, the
proportion of patients with RRFs was lower (63% vs.
96%). Interestingly, another small cohort study
(n = 15) also reported a much higher proportion of
patients with respiratory impairment (67%), with
nearly 50% of patients requiring either nocturnal venti-
lator support or tracheostomy with mechanical ventila-
tion [83]. Different ascertainment methodologies may
account for some of the discrepancies in prevalence
data; for example, the German study excluded 22 symp-
tomatic family members who had not been genetically
confirmed to carry m.8344A>G [97]; however, it is clear
from these cohort studies that the phenotypic spectrum
is wide and multisystemic and can overlap with pheno-
types associated with other pathogenic mtDNA vari-
ants, such as m.3243A>G (e.g. stroke-like episodes).
Both m.3243A>G and m.8344A>G present with
wide, overlapping clinical spectra. Consequently, iden-
tifying the underlying cause of a patient’s disease is
frequently dependent upon obtaining a molecular diag-
nosis. Although lipomas are more commonly associ-
ated with m.8344A>G, and a family history of
deafness and diabetes might point towards
m.3243A>G (Fig. 2), phenotypic features are diverse
and most patients, especially those with m.3243A>G,
do not fit a syndromic diagnosis. Therefore, in the
diagnostic setting, patients who are suspected of carry-
ing a pathogenic mtDNA variant will be screened for
a number of common variants, m.3243A>G and
m.8344A>G among them [98].
Currently, our understanding of the phenotypic
spectrum associated with both m.3243A>G and
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m.8344A>G is biased towards individuals who have
been referred for genetic testing, that is patients show-
ing symptoms linked to mitochondrial disease and
their relatives. However, an estimated 140–250 in
100 000 individuals carry the m.3243A>G variant
[99,100], which is 40–70 times higher than the esti-
mated disease prevalence of 3.5 in 100 000 [10]. This
implies that the proportion of asymptomatic carriers is
high. Disease prevalence (0.2 in 100 000) is far lower
for m.8344A>G, and we lack a good estimate of car-
rier frequency, but asymptomatic or mildly affected
carriers are also likely to be present in the general pop-
ulation [10,100]. Recent developments in the collection
of large population-based genetic and phenotypic data-
sets, such as the Genomics England’s 100 000 Gen-
omes Project and the UK Biobank [101,102], may
allow us to begin to build a more comprehensive pic-
ture of the phenotypic spectrum at a population level,
although the continued longitudinal and thorough
phenotype profiling that is performed within mito-
chondrial disease clinics and research environments
will continue to deepen our knowledge of the pheno-
types associated with these highly heterogeneous disor-
ders. This will be essential if we are to gain a deeper
understanding of the additional factors associated with
an increased likelihood of severe disease in individuals
who carry m.3243A>G or m.8344A>G.
Heteroplasmy and mtDNA copy number, disease
burden and progression
Both m.3243A>G and m.8344A>G are heteroplasmic
variants (Box 1). It is very tempting therefore to
hypothesise that the vast clinical heterogeneity
observed in individuals carrying these mt-tRNA vari-
ants could be attributed to differences in levels of the
variant allele between cells, tissues and individuals. In
reality, the relationship between pathogenic mt-tRNA
levels and clinical phenotype is not straightforward.
Both m.3243A>G and m.8344A>G are functionally
recessive in vitro; low levels (6–15%) of wild-type
mtDNA are capable of rescuing mitochondrial transla-
tion, complex IV activity and oxygen consumption to
near-normal levels [103,104]. However, the picture is
more complicated in vivo; high levels of m.3243A>G
have a dominant-negative effect in skeletal muscle
fibres, impeding rescue of the respiratory chain defect
by increased wild-type mtDNA copy number [105].
For both variants, mutation-associated phenotypes are
observed in some patients who harbour low levels of
mutated mtDNA, whereas some individuals with high
mutation levels only manifest mild symptoms
[97,106,107].
With regard to m.3243A>G, deciphering the rela-
tionship between the level of the pathogenic (G) allele
and disease burden or clinical phenotype is further
complicated by an age-related negative selection
against this G allele in easily sampled mitotic tissues,
such as the blood [108–111]; in contrast, levels in post-
mitotic tissues such as the muscle appear to be more
stable [106]. Blood levels can be corrected for age to
more accurately reflect the likely levels of m.3243A>G
within the postmitotic tissues most affected by the
mitochondrial dysfunction. Indeed, despite interindi-
vidual variation in the rate of this age-related decline,
age-corrected blood m.3243A>G levels are better cor-
related with total disease burden and progression than
urine levels and are just as good as muscle levels in
this respect [106]. Despite this, models using age and
age-corrected m.3243A>G levels can only explain
~ 27% of the variability in disease burden that we
observe. Increased muscle mtDNA copy number has
some protective effect (increasing the explained varia-
tion to ~ 40%), implying that a higher wild-type
mtDNA content may rescue mitochondrial dysfunc-
tion, but the lower mtDNA copy number in more
severely affected individuals may simply reflect decon-
ditioning of skeletal muscle due to decreased levels of
physical activity within these patients [106,112].
The relatively high frequency of m.3243A>G has
allowed the relationship between variant level and phe-
notype to be explored in large cohorts. The first of
these studies reported higher frequencies of severe neu-
rological phenotypes, such as stroke-like episodes, epi-
lepsy and ataxia, in patients with higher m.3243A>G
levels, but the opposite was the case for features such
as CPEO, myopathy and deafness; this apparent para-
dox may result from earlier presentations in individu-
als with neurological symptoms and highlights the
need to also consider age when studying progressive
disorders [96]. Later studies failed to use m.3243A>G
levels to predict specific phenotypes, although patients
with MELAS tend to have higher levels compared
with their carrier relatives [44,49,51]. Most recently, in
a cohort study of 238 adult carriers of m.3243A>G,
increasing mutation levels were significantly associated
with increasing severity of cerebellar ataxia, cognition,
neuropathy, dysphonia–dysarthria, seizures,
encephalopathy, stroke-like episodes, hearing impair-
ment, myopathy, diabetes and cardiovascular involve-
ment; cerebellar ataxia, neuropathy, hearing,
myopathy, diabetes and cardiovascular involvement
were more severe with increasing age [52]. Both
migraine and seizures were found to be more severe in
younger individuals, likely reflecting earlier presenta-
tions in these individuals. Hearing impairment,
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diabetes and cerebellar ataxia were the traits best
explained by mutation level and age, but only a small
proportion of the variability in all phenotypes was
explained by these factors (pseudo-R2 values ranged
from 0.02 to 0.17). Therefore, much of the phenotypic
variability we see in m.3243A>G-related disease
remains to be explained.
In the case of m.8344A>G, an early attempt to cor-
relate levels of the variant allele in muscle with clinical
phenotypes in 55 individuals (including cases from
both a clinical cohort and the literature) showed that
the frequency of myoclonus, ataxia, epilepsy, myopa-
thy, deafness and dementia was higher in individuals
with high levels. Of note, this cohort included only
two individuals with levels < 70%, possibly reflecting a
publication bias [96]. Two more recent studies have
failed to see significant relationships between mutation
level and clinical phenotype, although a nonsignificant
trend towards higher levels in patients with myopathy
was observed in the Italian cohort [95,97]. However,
conclusions are compromised by relatively low statisti-
cal power (sample sizes were 22 and 18). Thus, under-
standing the relationship between m.8344A>G level
and phenotype will require the analysis of larger
patient cohorts.
Segregation and clonal expansion
The phenomenon of heteroplasmy results in variable
levels of pathogenic mtDNAs being present in differ-
ent cells, tissues and individuals (Box 1) [108,113–115].
Moreover, the levels of m.8344A>G and m.3243A>G
are higher in cells that show defective OXPHOS com-
pared with biochemically normal cells from the same
tissue [116–120]. The level of mutation over which a
cell manifests OXPHOS deficiency (threshold level of
mutation) also differs between individuals, therefore, it
is possible that interindividual differences in this
threshold, as well as the cellular distribution of muta-
tion levels, could account for some of the clinical vari-
ability associated with mtDNA mutations [120].
The cause of these intraindividual differences in
mutation levels is not yet fully understood but is likely
to be linked to several processes. These include the fol-
lowing: differences in the rate of replication of gen-
omes containing wild-type and mutant alleles;
differential random segregation of mtDNA molecules
into daughter cells at cell division; and differences in
survival and replication rates of cells with differing
mutation levels. During embryo-fetal development,
mutation levels appear to be similar across different
tissues; therefore, variability of mutation level between
tissues is likely to take place after this early
developmental phase [121]; whether there is variability
between single cells at this stage is unknown. The con-
trol of mtDNA replication can be linked to the cell
cycle (‘strict replication’), but the mitochondrial gen-
ome is also able to replicate independently of the cell
cycle in a process termed ‘relaxed replication’
[122,123], which may also contribute to clonal expan-
sion and therefore cell-to-cell variability, even within
postmitotic tissues. Simulation studies show that the
clonal expansion of mtDNA point mutations can be
explained by the process of differential segregation due
to random drift [124] and extensively reviewed in [125].
However, nuclear control of tissue-specific mtDNA
segregation has been demonstrated in mice and similar
patterns of m.3243A>G tissue segregation have been
described in two sets of identical twins, suggesting that
this process may not be fully random [126,127].
Pathogenicity of the m.8344A>G mt-
tRNALys and m.3243A>G mt-tRNALeu
(UUR) variants
The development of therapies for mitochondrial dis-
ease is a rapidly evolving area, with efforts focussed
on discovering small molecules that can improve
OXPHOS function, developing potent antioxidant
molecules, delivering therapies that can reduce the pro-
portion of mutant mtDNA in affected tissues and pre-
venting the transmission of pathogenic mtDNA
variants (reviewed extensively in [128]). To develop
effective therapies for patients with mitochondrial dis-
ease, a complete understanding of the specific molecu-
lar mechanisms and key factors that sustain mtDNA
expression is essential. Mitochondrial diseases are clini-
cally heterogeneous, and some pathogenic variants dis-
play striking tissue specificity (e.g. lipomas associated
with m.8433A>G and retinal nerve atrophy associated
with variants in mitochondrially encoded complex I
genes) [129]. In stark contrast to this complex clinical
picture, the current prevailing view on the aetiology of
these clinical features is that they are caused by
OXPHOS deficiency. General aberrations in mitochon-
drial genome expression are likely to generate an
OXPHOS defect, but the question remaining then is
‘Why are these mitochondrial diseases so heteroge-
neous?’ We and others have proposed that this is due
to variation in the underlying molecular mechanism
for each mtDNA mutation, but addressing this ques-
tion experimentally is complicated by differences in
heteroplasmy (see Box 1) across specific cell types and
tissues in patients.
Pathogenic variants in mt-tRNA genes can desta-
bilise the mt-tRNA molecule, prevent efficient or
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correct aminoacylation and/or affect the interaction
with elongation factor Ef-Tu and the ribosome. As a
consequence, mitochondrial protein synthesis is per-
turbed. Hence, steady-state protein levels of the 13
mtDNA-encoded proteins are reduced resulting in
diminished respiratory chain complex abundance.
While the frequencies of UUR (Leu) and AAR (Lys)
codons are similar in human mtDNA-encoded pro-
teins, some complexes are preferentially affected
depending on the frequency of the encoded amino acid
in the specific subunit [130]. Thus, respiratory chain
dysfunction clearly is a direct consequence of the pri-
mary molecular defect, and redox state and energy-
generating capacity of the affected cells and tissues are
compromised. The level of the variant allele in patient
tissues is clearly one major factor that can determine
disease severity and progression; however, as discussed
above, for m.3243A>G and m.8344A>G, variant levels
are not strictly correlated with disease severity, age of
onset or the rate of progression. For m.3243A>G,
levels of the variant allele diminish over time in mitotic
tissues; the molecular mechanism of this is not fully
understood but is likely to be related to cell division
(Box 1) [111]. Mitochondrial translation-dependent
proliferation defects have been attributed to deficient
aerobic energy metabolism, even though proliferating
cells rely primarily on glycolysis to meet their meta-
bolic demands. Studies using small molecule inhibitors
of mitochondrial translation have indicated that a
defect in cell proliferation can occur before OXPHOS
is impaired and it has been speculated that the health
of mitochondrial translation itself might be an impor-
tant checkpoint for cell cycle progression [131–133].
The demand for OXPHOS is very high after birth,
indicating the prevalence of glycolytic metabolism dur-
ing fetal development and indispensability of
OXPHOS for postnatal maintenance of human tissues
[134]. Therefore, significant loss of respiratory chain
capacity offers a consistent rationale for the rapidly
progressing disease onset soon after birth, with organ
failure and lactic acidosis. However, even with rela-
tively high variant levels of m.3243A>G or
m.8344A>G and concomitant loss of respiratory chain
complexes, a great number of patients develop pro-
gressive disorders only later in life. This indicates that
patient-specific modifiers exist and that specific organs
have distinct age-dependent sensitivity to respiratory
chain dysfunction. It is also in line with studies on the
coevolution of mtDNA-encoded tRNAs and their cog-
nate mt-aaRSs [7] and direct evidence for the existence
of nuclear modifiers comes from the observation that
overexpression of human mt-leucyl-tRNA synthetase is
sufficient to improve the viability of m.3243A>G cells
when grown in galactose [135]. Interestingly, overex-
pression of the carboxy-terminal domain alone was
both necessary and sufficient for the rescue [136]. The
hypothesis that mt-aaRSs have the capacity to modify
disease outcomes in m.3243A>G warrants the screen-
ing for disease-modifying SNPs of the cognate mt-
aaRSs in a large cohort of m.3243A>G patients.
Molecular mechanisms
In recent years, tremendous progress has been made in
deciphering the primary insults causing mitochondrial
gene expression disease. Avoiding the limitations of
studying pathogenic mtDNA variants in transmito-
chondrial cybrids (cybrids), Shoubridge et al. selected
clones of patient myoblasts homoplasmic for
m.3243A>G and m.8344A>G, studying control cells,
homoplasmic for wild-type mtDNA, from the same
patient. This tour de force established cell culture
model systems to investigate homoplasmic mutant cells
and use wild-type mtDNA cells with the same nuclear
genetic background as controls for both m.8344A>G
and m.3243A>G patient myoblasts [103,130]. These
cell lines have been extremely valuable in isolating the
primary molecular aberrations and their downstream
consequences for both m.8344A>G and m.3243A>G.
Because mitochondrial gene expression is dependent
on two interacting genomes, these myoblasts provide
the gold standard, avoiding the use of cell models with
unstable and transformed nuclear backgrounds. Unlike
HEK293 cells, the m.8344A>G patient myoblasts clo-
sely recapitulate the molecular findings from patient
muscle samples [137]. Studies of the molecular mecha-
nisms underlying both m.8344A>G and m.3243A>G
should make use of this study system.
The pathogenic m.3243A>G variant causes impaired
recognition of UUA and UUG codons but only minor
aberrations in translation elongation rates; amino acid
misincorporation consequently induces the decreased
stability of de novo-synthesised mtDNA-encoded pro-
teins [103,130]. mt-tRNA molecules require a wide
variety of post-transcriptional modifications, which
stabilise mt-tRNA structure, enable efficient interac-
tion with the ribosome and ‘fine-tune’ mitochondrial
translation (Fig. 1B). In m.3243A>G, the taurine mod-
ification at the wobble position in mt-tRNALeu(UUR) is
disrupted, which in turn causes the mt-tRNA to
decode all UUX codons [138]. Thus, misincorporation
as the primary molecular phenotype ultimately causes
lack of respiratory subunits and OXPHOS deficiency.
Importantly, it also provokes a burden on the inner
membrane proteostasis machinery dealing with unsta-
ble respiratory complex complex intermediates and
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very hydrophobic, polytopic and de novo-synthesised
respiratory chain subunits [139]. These proteins are
associated with iron sulfur clusters and haem mole-
cules already inserted into the inner membrane and
need to be recognised and extracted from the mem-
brane by chaperones. Subsequently, degradation by
dedicated proteases has to occur. Considering the elec-
trochemical charge across the inner mitochondrial
membrane, this quality control system for newly syn-
thesised respiratory chain subunits is especially chal-
lenging for the cell.
More recently, a second modification 2-methylthio-
lation (ms2) was also found to be decreased in
m.3243A>G cells [140]. However, since the mt-tRNA-
Leu(UUR) is not ms2 modified itself – the modification is
reduced on mt-tRNAs decoding Phe, Tyr, Trp and Ser
codons – this argues for feedback regulatory mecha-
nisms adapting the modification status of mt-tRNAs
in response to aberrant mitochondrial translation. This
is further substantiated by the observed correlation of
heteroplasmy level with the ms2 modification level in
patients [140] and raises the question of which signals
transmit and induce this stress response. While reactive
oxygen species have been proposed to be the causative
entity [140], a more general interpretation entirely con-
sistent with the current data might be that redox
changes are involved in signalling the health status of
mitochondrial translation. Taken together, the analysis
of the primary molecular aberration predicts that the
m.3243A>G variant produces both loss and gain of
function phenotypes. This is in line with the above-de-
scribed patient phenotypes associated with
m.3243A>G, where patients with low levels of the vari-
ant allele develop disease, and no clear threshold for
expression of the mutation is observed in some tissues
[107,141].
Another recent study has suggested that heteroplas-
mic cells and tissues generated through induced
pluripotent stem cell (iPSC) reprogramming technol-
ogy could be an excellent tool to study tissue-specific
manifestations and mechanisms of pathogenesis in
m.3243A>G [142]. The same study shows the mtDNA
bottleneck also occurs during reprogramming of
m.3243A>G iPSCs, making it a very useful tool to
generate and study the impact of varying levels of the
pathogenic variant in vitro. Furthermore, the authors
provide evidence that early-differentiating neurons
show loss of respiratory complex I. Directly measuring
protein turnover rates of the respiratory chain subunits
from all five complexes would greatly support the
claim of active complex 1 degradation in the early neu-
rons. In the light of the heterogeneity of tissue-specific
respiratory chain complex deficiency patterns, insight
into a mechanism that actively degrades specific com-
plexes would be a tremendous step forward in our
understanding of in m.3243A>G tissue-specific disease
manifestation and allow us to identify the tissue-speci-
fic factors and machinery involved in this process
in vitro.
In stark contrast to m.3243A>G, the m.8344A>G
mt-tRNALys variant causes a very severe translation
defect during mitochondrial protein synthesis, readily
observable by 35S-metabolic labelling [103,130,137].
Decreased steady-state abundance of mt-tRNALys,
reduced aminoacylation of the mt-tRNA, and lack of
a post-transcriptional RNA modification of the anti-
codon wobble base [143–146] have all been correlated
with the aberrant translation pattern. However, the
pattern observed from metabolic labelling of mito-
chondrial proteins was not consistent with random
premature termination at lysine codons. Instead, in
cells homoplasmic for m.8344A>G, distinct aberrantly
sized and full-length polypeptides have been observed
[130,137]. Pulse and pulse–chase metabolic labelling
experiments clearly demonstrate that the aberrantly
sized chains are unstable, but interestingly, all full-
length nascent chains are also unstable [103,130,137].
Reports with contradicting results have been pub-
lished, but all these studies have been based on cybrids
or in vitro translation experiments, both of which are
not suited to closely recapitulate mitochondrial protein
synthesis in tissues of MERRF patients [137].
Thus, even though m.3243A>G and m.8344A>G
both decrease the steady-state abundance of the assem-
bled respiratory chain complexes and ATP synthase,
they have different primary molecular aberrations,
which may have cellular implications beyond
OXPHOS. Different processes are therefore required
to resolve insults from these specific primary aberra-
tions in mitochondrial protein synthesis, and it is these
processes that are likely to determine the molecular, if
not the clinical, phenotype. Additionally, tissue- and
cell type-specific stress responses are likely serving as
modifiers of mitochondrial disease phenotypes. While
aimed to rectify the initial insult by the mt-tRNA
mutation, such stress responses can get deleterious,
especially when they become chronic. Both
m.3243A>G and m.8344A>G patients show the induc-
tion of the mitochondrial integrated stress response
ISRmt with high circulating serum levels of FGF21
and GDF15 [147]. Importantly, in mice, inhibition of
the chronic ISRmt has been shown to be protective
[148].
A more detailed understanding of the specific factors
required for the quality control processes is needed
and could cast light on the molecular mechanism
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behind the different tissue specificities (and therefore
clinical manifestations) of m.3243A>G and
m.8344A>G. Recently, a methodological advance in
next-generation RNA sequencing allowed Richter
et al. to investigate the consequences of homoplasmic
m.8344A>G variant levels on the stoichiometry and
modifications of all mt-tRNAs in affected patient tis-
sues and in the above-described homoplasmic
m.8344A>G myoblasts. Contrasting the results in
HEK293T cells and cybrids, homoplasmic m.8344A>G
myoblasts faithfully represented the molecular muscle
phenotype with steady-state level and wobble base
modification specifically reduced on mt-tRNALys only
[137].
The results also uncovered a prevalent and unsus-
pected influence of RNA modifications on mitochon-
drial gene expression in general and revealed the role
of a second mt-tRNA methyl modification at position
A8348 (besides the wobble base taurine modification)
in the pathogenesis of MERRF. The mutant mt-tRNA
appears largely unable to efficiently decode lysine dur-
ing translation elongation, and in contrast to the
m.3243A>G mutation, elongation rates are severely
reduced in m.8344 A>G myoblasts [103,130,137]. The
impact of the second mt-tRNA methyl modification at
position A8348 was revealed by overexpression of the
writer enzyme TMRM61B (Fig. 1B). While re-estab-
lishing the modification to control levels rescued the
translation elongation phenotype, all translation prod-
ucts were still unstable, mimicking the molecular trans-
lation phenotype observed in m.3243A>G myoblasts.
Conversely, overexpressing the TMO1 part of the wri-
ter enzyme complex of the mnm5s2U34 wobble uridine
base rescued both the elongation rate and stability of
all mitochondrial translation products [137]. Because
MTO1 activity is directly correlated with mitochon-
drial translation fidelity, enhancing fidelity but not
translation initiation or elongation rate would be an
attractive therapeutic avenue in both m.3243A>G and
m.8344A>G-related mitochondrial disease. Enhanced
fidelity is advantageous when compared with enhanc-
ing translation per se, because it prevents mitochon-
drial translation quality control systems from getting
overwhelmed [5].
Together, these findings strongly suggest that the
expression levels of mt-tRNA modification factors
could be modifiers of mt-tRNA-associated disease and
partly explain the highly variable tissue-dependent phe-
notypes. The very specific molecular aberrations
observed in m.8344A>G are also in line with the view
that the mutation causes a strong burden on ribosome
quality control where severe stalling of the mitochon-
drial ribosomes during translation elongation occurs.
Rescuing ribosomes that fail to synthesise full-length
polypeptides requires a rescue pathway to recover the
stalled ribosomes, including endo- and exoribonuclease
activity to cleave the mRNA, a release factor to catal-
yse the cleavage of the ester bond of the peptidyl-mt-
tRNA, and chaperones and proteases to recognise and
degrade the premature translation product. It is there-
fore unsurprising that pathogenic variants in mt-
tRNAs present as a heterogeneous class of diseases
with varying severity and variable tissue specificity. We
are just starting to understand the multiple layers and
factors involved in the modification of molecular
insults from both mutations; discovering more modify-
ing factors by utilising the ever-expanding genetic tool
kit, and importantly primary patient material, will
likely be a very fruitful avenue to pursue in the near
future. For both m.3243A>G and m.8344A>G, we
postulate that the molecular mechanisms driving
pathology are multilayered, consisting of a combina-
tion of multiple patient- and tissue-dependent factors
from mt-tRNA stoichiometry, modification, aminoacy-
lation and their quality control through to translation
elongation speed and fidelity. Disease manifestation
will also be affected by nascent chain handling and
proteolytic quality control of the 13 mtDNA-encoded
proteins and by cellular stress responses that not only
modify the coordination of the gene expression from
both nuclear and mitochondrial genomes but also
drive metabolic changes in the patients.
Mito-nuclear crosstalk
Current estimates place ~ 1500 proteins within the
mitochondrial proteome, and with only 13 of these
encoded by the mitochondrial genome, mito-nuclear
communication is key to maintaining optimal mito-
chondrial function and determining how a cell
responds to metabolic challenges. Indeed, mitochon-
dria are critically dependent on the coordination of
genetic information from both the nuclear and mito-
chondrial genomes [133,149–152]. Characterisation of
the communication between these two organelles has
revealed a complex and sophisticated bidirectional sys-
tem involving both anterograde (nuclear to mitochon-
drial) and retrograde (mitochondrial to nuclear)
signalling pathways. We are only beginning to recog-
nise the importance of these communication networks
and how they are deployed in mitochondrial diseases.
It has been demonstrated that small changes in
m.3243A>G variant level in cybrids can cause large
shifts in cellular phenotype and gene expression pro-
files, despite much smaller effects on oxidative capac-
ity, indicating retrograde signalling and demonstrating
1014 FEBS Letters 595 (2021) 1003–1024 ª 2021 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
Pathogenic mitochondrial tRNA variants U. Richter et al.
the capacity of the nucleus to respond to mitochon-
drial changes related to mtDNA mutations [52,153].
NAD+/NADH and a-ketoglutarate/succinate ratios
have been shown to mediate some of these transcrip-
tional changes [154]; these experiments confirm that
the presence of pathogenic mt-tRNA variants at differ-
ent levels can bring about epigenetic and transcrip-
tional changes and that some of these are mediated by
changes in the metabolic status of the mitochondria.
The rewiring of cellular metabolism and regulation
of nuclear and mitochondrial transcription in response
to mitochondrial dysfunction involves initiation of the
ISRmt, but we are only just beginning to understand
how this response is triggered. Recently, Fessler et al.
identified a pathway that may constitute a missing
piece in this puzzle, demonstrating that the stress-in-
duced activation of OMA1, an inner membrane mito-
chondrial protease, leads to the cleavage of DELE1
and its accumulation in the cytosol; subsequent bind-
ing of this shortened form of DELE1 to HRI (an
eIF2ɑ kinase) triggers the expression of the transcrip-
tional regulator C/EBP homologous protein (CHOP),
a key component of the ISRmt, which is induced upon
misfolding of proteins in the mitochondrial matrix and
aberrations in mitochondrial gene expression [148,155–
157]. It is now crucial to study the impact and dynam-
ics of this pathway in response to the presence of both
m.3243A>G and m.8344A>G to understand its impor-
tance in health and disease, more specifically in aberra-
tions where mitochondrial protein synthesis is
disrupted either by ribosomal stalling or by amino acid
misincorporation.
Very recently, digenic inheritance of mtDNA and
nuclear variants has been demonstrated for reversible
infantile respiratory chain deficiency, which is associ-
ated with the homoplasmic m.14674T>C mt-tRNAGlu
variant, but shows reduced penetrance [158,159]. In
affected patients, Hathazi et al. discovered additional
rare, heterozygous nuclear mutations in EARS2 and
TRMU, which encode proteins responsible for aminoa-
cylation of mt-tRNAGlu and mt-tRNAGln and cys-
teine-dependent thiouridylation of mt-tRNAGlu, as
well as other genes involved in glutamate or glutamine
metabolism. Studying the transcriptome and proteome
within skeletal muscle from these patients, who
undergo spontaneous recovery by 5–20 months of age,
revealed that the ISRmt is triggered in early life (char-
acterised by increased FGF21 and GDF15 expression),
and is followed by an increase in metabolism modu-
lated by serine biosynthesis, one-carbon metabolism,
lipid oxidation within the TCA cycle and amino acid
availability. The authors hypothesise that this subse-
quently leads to mTOR-dependent increased
mitochondrial biogenesis and recovery from the respi-
ratory chain deficiency [159]. Given the protective
effect of increased mtDNA copy number in muscle
that we see in m.3243A>G-related disease [106] and
the increased FGF21 and GDF15 expression observed
in patients with MERRF and MELAS [147], it is pos-
sible that a similar mechanism is operating in response
to other pathogenic mt-tRNA variants. Interindividual
variation in the effectiveness of this response may con-
tribute to differences in disease burden between
patients with similar levels of mutation. However,
unlike m.14674T>C, m.3243A>G and m.8344A>G are
heteroplasmic variants and the disease they cause is
more heterogeneous and not reversible; teasing out the
factors that affect clinical presentation is going to be
hugely challenging.
Future directions
We cannot explain and do not understand what causes
the majority of the phenotypic variability in patients
carrying m.3243A>G and m.8344A>G. The levels of
mutated mtDNA and patient’s age are thought to be
involved but variation within nuclear genes is also a
strong contender. Recent pedigree analyses suggest
that additive genetic factors play a considerable role in
the severity of a number of m.3243A>G-related pheno-
types. Moderate to high heritability estimates were
obtained for psychiatric involvement, hearing impair-
ment, ataxia, migraine and cognition [52]. Interest-
ingly, the presence of encephalopathy was also shown
to be heritable. Yet, high levels of m.3243A>G alone
are not sufficient to explain the presence of the most
severe and life-limiting phenotypes associated with this
mtDNA variant. Although similar studies have not yet
been performed for m.8344A>G, the lack of strong
association of phenotypes with the proportion of the
variant allele suggests that variation within nuclear
genes may also contribute to the wide clinical hetero-
geneity associated with this variant. Indeed, there may
be some overlap. Identifying these nuclear variants will
give us more clues as to the molecular mechanisms
underlying the pathogenicity of mt-tRNA variants,
identify potential therapeutic targets and could
improve genetic counselling.
To this end, two complementary approaches can be
employed to identify additional nuclear factors that
are key to understanding the molecular mechanism
and hence the phenotypic expression of these mt-
tRNA variants. The first is hypothesis-driven, building
on the knowledge we already have of the molecular
mechanisms of pathogenicity and molecules involved
in mito-nuclear crosstalk to identify further interacting
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molecules in these pathways. This approach has
already been successful in a mouse model of neurode-
generation caused by aberrant mitochondrial inner
membrane structure [160] and in the nonstop MT-
ATP6 mRNA (m.9205delTA) patient cell line [161].
Also, it has been shown previously that in cell lines
harbouring -tRNA mutations, overexpression of the
cognate mt-aaRSs can suppress the mutant phenotypes
[162,163].
The second is a knowledge-discovery approach,
which is not limited by current knowledge and has the
potential to uncover unknown pathways and molecu-
lar mechanisms of disease. Combining both
approaches will likely prove to be more powerful than
either in isolation.
Knowledge-discovery approaches employ methods
such as genetic linkage analysis, genome-wide genetic
association (GWAS) and whole-genome/exome
sequencing to systematically search the nuclear genome
for regions and variants that modify phenotype. This
has been hugely successful in recent years at identify-
ing nuclear risk factors for a wide range of complex
traits; the GWAS catalogue contains over 70 000 vari-
ant–trait associations and is constantly growing
[164,165]. Applying these methods to mt-tRNA dis-
eases requires the collation of large, deeply pheno-
typed, patient cohorts and pedigrees, requiring strong
collaborations between basic scientists and clinicians
across the world, and a systematic approach to pheno-
typing. The rare nature of mtDNA-related disease will
result in smaller cohorts than those typically utilised
for common disorders, but genetic variation with large
effect sizes should be identifiable, even in modestly
sized studies, particularly if information from families
is incorporated into the analyses [166]. Whole-genome
sequencing and whole-exome sequencing are likely to
be more effective than GWAS-based approaches if
there is genetic heterogeneity, as is the case with sec-
ondary pathogenic nuclear variants necessary for the
phenotypic expression of the homoplasmic
m.14674T>C variant [159]. More recently, whole-gen-
ome sequencing and whole-exome sequencing have
been applied to large population-based cohorts, such
as the UK Biobank and Genomics England’s 100 000
Genomes Project, enabling the identification of further
carriers of mtDNA mutations within populations;
these may be valuable resources that can be used for
validation studies [101,102].
By using the knowledge gained from identifying the
nuclear factors involved in the complex molecular
pathology of mt-tRNA-related mitochondrial disease,
we will be able to inform and direct further hypothe-
sis-driven studies, characterising the essential pathways
and networks responsible for determining cellular fate
in response to defects in mitochondrial translation.
These advances and elegant patient-derived cell culture
techniques have the capacity to transform our under-
standing of the molecular pathogenesis and the basis
of the extreme clinical heterogeneity that is associated
with pathogenic variants in mt-tRNA genes. Such
knowledge will be instrumental to identify potential
targets for improved diagnostics and pharmacological
treatment for patients with no treatment option to
date.
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